anti-CD155 (PVR) (human) mAb (ANC2B2)
| Code | Size | Price |
|---|
| ANC-255-020-100ug | 100 ug | £243.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Antibody Clone: ANC2B2
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
BI
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
PVR; Polio Virus Receptor
EClass:
32160000
Form (Short):
liquid
Formulation:
50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant human CD155.
Long Description:
Monoclonal Antibody. Isotype: Mouse IgG1kappa. Clone: ANC2B2. Applications: ELISA, FACS. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin sulfate. Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70kd type I Ig superfamily molecule. It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226 (DNAM-1), and CD96 (TACTILE). CD155 expression by tumor has been shown to be upregulated by nitric oxide. A soluble version of CD155 has been shown to exist. High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma.
Package Type:
Plastic Vial
Product Description:
Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70kd type I Ig superfamily molecule. It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226 (DNAM-1), and CD96 (TACTILE). CD155 expression by tumor has been shown to be upregulated by nitric oxide. A soluble version of CD155 has been shown to exist. High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma.
Purity:
>95% (SDS-PAGE)
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD155 (PVR) (human) mAb (ANC2B2) (Biotin) | ANC-255-030 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD155 (PVR) (human), mAb (ANC6A3) | ANC-350-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD155 (PVR) (human), mAb (ANC6A3) (Biotin) | ANC-350-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CD155 (PVR)-muIg Fusion Protein | ANC-555-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CD155 (PVR)-muIg Fusion Protein (Biotin) | ANC-555-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||